G01N33/582

METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS
20230037660 · 2023-02-09 ·

Compositions and formulations comprising peptide conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to detectable agents or active agents. Methods of detecting and treating vascular lesions, vascular malformations, and vascular abnormalities including cerebral cavernous malformation (CCM) with peptide conjugate compounds are also provided, including methods of imaging and resecting vascular lesions tissues and cells.

CA IX-NIR dyes and their uses

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to the active site of carbonic anhydrase, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid, amide, ureido, or polyethylene glycol derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Dye compounds and the use of their labelled conjugates

Novel rhodamine dye compounds, labelled conjugates comprising the dyes are described, together with methods for their use. The dyes and labelled conjugates are useful as molecular probes in a variety of applications, such as in assays involving staining of cells, protein binding, and analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing.

RNA interference agents for GST-PI gene modulation

This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

Control marker for implementing analysis methods on spots

The present invention relates to the use of a control marker for implementing analysis methods on spots, in particular in the context of multiplex analyses. The present invention thus relates to solid supports containing said control marker, their preparation method and their use in analysis methods. The present invention makes it possible to verify the presence, location and/or integrity of the spots at the end of the analysis method, and thus to secure the obtained results while guaranteeing that the yielded result indeed results from a present, intact and localized spot.

BENZOPYRYLIUM COMPOUNDS

Compounds used as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

UNIVERSAL ASSAY FOR DETERMINING THE QUANTITY OF TNFa INHIBITORY DRUGS AND THEIR CORRESPONDING ANTI-DRUG-ANTIBODIES
20180003719 · 2018-01-04 · ·

The present invention relates to a kit of parts and methods for determining the presence and quantity of one or more TNF-α inhibitor drugs and/or anti-TNF-α inhibitor drug antibodies in one or more biological samples each comprising less than 200 μl, the method comprising the steps of providing a reaction liquid comprising the sample, a first TNF-α conjugate comprising TNF-α and a first conjugated moiety and a second TNF-α conjugate comprising TNF-α and a second conjugated moiety, said second moiety being capable of generating or ameliorating a detectable signal in the presence of a molecular complex comprising a TNF-α inhibitor, followed by detecting the change in signal when the complex between the TNF-α inhibitor drug, the first TNF-α conjugate and a the second TNF-α conjugate forms.

DETECTION APPARATUS AND DETECTION METHOD

Disclosed is a detection apparatus that transfers magnetic particles through a plurality of chambers in a cartridge which includes the plurality of chambers and a channel connecting between the plurality of chambers, and that causes the magnetic particles to carry a complex of a test substance and a labelling substance, to detect the test substance on the basis of the labelling substance in the complex. The detection apparatus includes: a rotation mechanism configured to rotate the cartridge about a rotation shaft; a magnet configured to collect the magnetic particles in the chambers; a movement mechanism configured to move the magnet in a direction different from a circumferential direction of a circle in which the rotation shaft is centered; a detector configured to detect the test substance; and a controller programmed to control the rotation mechanism and the movement mechanism so as to transfer the magnetic particles from one of the chambers to another one of the chambers.

MULTIMERIC COMPOUNDS OF A KRINGLE DOMAIN FROM THE HEPATOCYTE GROWTH FACTOR / SCATTER FACTOR (HGF/SF)

Disclosed are multimeric compounds of K1 domains from the Hepatocyte Growth Factor/Scatter Factor (HGF/SF) being able to induce activation of the tyrosine kinase receptor MET and their uses.

REACTIVE LABELLING COMPOUNDS AND USES THEREOF
20180011104 · 2018-01-11 ·

Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.